amphotericin b liposome / Generic mfg.  >>  Phase 4
Welcome,         Profile    Billing    Logout  

7 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
amphotericin b liposome / Generic mfg.
ACTRN12612000367842: Feasibility of using single dose liposomal Amphotericin B for the treatment of Visceral Leishmaniasis in Bangladesh

Recruiting
4
300
 
World Health Organization, World Health Organization
Visceral leishmaniasis
 
 
2008-008382-35: Open , multicenter, randomized trial comparing two therapeutic approaches for the treatment of invasive fungal infections in neutropenic onco-hematologic patients.Empiric vs. ``presumptive`` (preemptive) antifungal therapy.

Ongoing
4
270
Europe
Solution for infusion, Powder and solvent for solution for infusion, ABELCET, CANCIDAS, AMBISOME
Azienda Ospedaliera di Perugia
opportunistic fungal infections in neutropenic onco-hematologic patients
 
 
2007-001795-37: WIRKORTKONZENTRATIONEN VON AMPHOTERICIN B FORMULIERUNGEN IN ASZITES, LIQUOR, PLEURAERGUSS, GALLE UND LIQUOR BEI KRITISCH KRANKEN(Target-site concentrations of Amphotericin B preparations in ascites, pleural effusion, bile and cerebrospinal fluid in critically ill patients)

Ongoing
4
24
Europe
Amphocil, AmBisome, Abelcet, Amphotericin B \"BMS\", ABCD, LAMB, ABLC, AMB, Amphocil, AmBisome, Abelcet, Amphotericin B \"BMS\", Amphocil, AmBisome, Abelcet, Amphotericin B \"BMS\"
Medical University Innsbruck, Dpt. Internal Medicine, Div. Internal Medicine
Plasma and target-site (ascites, pleural effusion, bile and cerebrospinal fluid) concentrations of amphotericin B preparations will be measured in critically ill patients, requiring treatment with a amphotericin b preparation and requiring pleuracentesis, abdominal paracentesis, lumbar puncture or bile sampling for diagnostic or therapeutic reasons, to determine penetration of the drugs to target site.
 
 
2005-003406-28: Pharmakokinetik von lipid-formuliertem Amphotericin B unter Albumindialyse(Pharmacokinetics of lipid-formulated amphotericin B during albumin dialysis)

Ongoing
4
12
Europe
Amphocil, AmBisome, Abelcet, ABCD / LAMB / ABLC, Amphocil, AmBisome, Abelcet, Amphocil, AmBisome, Abelcet
Medical University, Dpt. Internal Medicin, Division of General Inteal Medicine
Plasma concentrations of lipidformulated amphotericin B will be measured in patients requiring treatment with lipid-formulated amphotericin B for systemic fungal infection (proven or suspected) and impaired renal function as well as albumin dialysis for cholestatic liver failure.
 
 
2005-003609-96: Amphotericin B Spiegel in bronchoalveolären Lavagen (Epithelial Lining Fluid) unter Behandlung mit lipidformuliertem Amphotericin B(Amphotericin B levels in broncho-alveolar lavage [epithelial lining fluid] during treatment with lipid-formulated amphotericin B)

Ongoing
4
45
Europe
Amphocil, AmBisome, Abelcet, ABCD / LAMB / ABLC, Amphocil, AmBisome, Abelcet, Amphocil, AmBisome, Abelcet
Medical University, Dpt. Internal Medicin, Division of General Internal Medicine
Plasma and ELF concentrations of lipidformulatied amphotericin b will be measured in patients requiring treatment with lipid-formulated amphotericin B for fungal pneumonia (proven or suspected).
 
 
2015-001566-26: A B-D-GLUCAN DRIVEN ANTIFUNGAL STEWARDSHIP APPROACH TO MANAGE EMPIRICAL THERAPY IN PATIENTS AT VERY HIGH RISK FOR INVASIVE CANDIDIASIS: A RANDOMIZED CONTROLLED TRIAL Una strategia di governo della terapia antifungina guidata da determinazioni seriate del BETA-D-GLUCANO (BDG) in una popolazione di pazienti ad alto rischio per candidiasi invasiva: studio controllato randomizzato

Ongoing
4
180
Europe
TYGACIL, merrem, Tazocin, cancidas, ecalta, ambisome, TYGACIL, merrem, tazocin, cancidas, ecalta, ambisome, Powder for solution for infusion, Powder for solution for injection, TYGACIL - 50 MG POLVERE PER SOLUZIONE PER INFUSIONE 10 FLACONCINI DI VETRO 5 ML, MERREM - 500 MG POLVERE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 10 FLACONCINI, TAZOCIN - 4 G + 0.500 G POLVERE PER SOLUZIONE PER INFUSIONE 12 FLACONCINI DI POLVERE, CANCIDAS - 50 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE ENDOVENOSA 1 FLACONCINO 10 ML, ECALTA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO-FLACONCINO (VETRO) DA 30 ML 1 FLACONCINO, AMBISOME - 50 MG POLVERE PER SOLUZIONE PER INFUSIONE 10 FLACONCINI
AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI, AOU di Bologna (fondi per la ricerca)
invasive candidiasis candidiasi invasiva, invasive candidiasis candidiasi invasiva, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2017-001433-74: Screening Anti-Fungal Exposure in Intensive Care Units – The French Cohort

Completed
4
40
Europe
Powder for concentrate for dispersion for infusion, Powder for solution for infusion, AmBisome Liposomal Amphotericin B 50mg Powder for Concentrate for Dispersion for Infusion., ECALTA 100 mg powder for concentrate for solution for infusion, CANCIDAS 50 mg powder for concentrate for solution for infusion, Diflucan 150 mg hard capsules, CRESEMBA 200 mg powder for concentrate for solution for infusion, Mycamine 50 mg powder for solution for infusion, Noxafil® 300 mg concentrate for solution for infusion, Voriconazole 200 mg powder for solution for infusion
CHU de NIMES, CHU NIMES
The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, The study will recruit patients in intensive care unit prescribed to receive any of the chosen systemic antifungal agents, Not possible to specify
 
 

Download Options